Moderna raised its full-year 2026 revenue-growth outlook to 15%–25%, compared with its previous expectation of up to 10%. This is the company's forecast, not a completed result. Its third-quarter revenue increased 29% to $1.31 billion, primarily reflecting higher international COVID vaccine sales. GAAP net income was $162 million, versus a $200 million loss a year earlier.
The company now expects year-end cash and investments of approximately $8.1 billion to $8.3 billion, up from its previous $4.7 billion to $5.2 billion range. The higher estimate reflects operating performance and proceeds from a convertible-notes financing, so the change should not be read as operating cash generation alone.
Watch the Moderna Short. Read the SEC-filed earnings release. The TradingView chart shows completed daily candles through the November 5 close, before this release and without November 6 premarket trading. Explore Daily Levels.
Company outlooks are the company's own. This is market research only, not a recommendation to buy or sell.